Mallinckrodt Completes Merger with Endo to Form Global Therapeutics Leader
August 1, 2025
Mallinckrodt plc and Endo, Inc. completed their merger to create a global, scaled, diversified therapeutics leader. The transaction combines Mallinckrodt’s branded portfolio with Endo’s generics and sterile injectables business (Par Health), which is intended to be spun off as a standalone independent company targeted for the fourth quarter of 2025.
- Buyers
- Mallinckrodt plc
- Targets
- Endo, Inc.
- Industry
- Pharmaceuticals
- Location
- Ireland
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.